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Is smaller better? Vaccine targeting recombinant receptor-
binding domain might hold the key for mass production of
effective prophylactics to fight the COVID-19 pandemic
Manish Muhuri1,2 and Guangping Gao1,2,3
Signal Transduction and Targeted Therapy           (2020) 5:222 ; https://doi.org/10.1038/s41392-020-00317-1
A recent report by Yang et al. published in Nature reported a
recombinant vaccine utilizing recombinant receptor-binding
domain (RBD) of SARS-CoV-2 Spike Protein.1 This vaccine
candidate successfully induced potent functional antibody
responses in the immunized mice, rabbits, and non-human
primates. The study highlights the critical role of the immuno-
genicity of the RBD domain upon SARS-CoV-2 infection and the
alternate vaccine designs that could serve as effective prophylac-
tics against the pandemic.
Coronavirus disease 2019 (COVID-19) is a type of viral
pneumonia that is caused by severe acute respiratory
syndrome–coronavirus 2 (SARS-CoV-2). The virus is highly
transmissible between humans and has spread rapidly (estimated
R0= 5.7), causing a worldwide pandemic that has had a
devastating impact on global health and the world economy. As
of August 8, 2020, almost 20 million people worldwide have been
infected with SARS-CoV-2 and more than 750,000 deaths have
been reported.2 Along with SARS-CoV and Middle East respiratory
syndrome–coronavirus (MERS-CoV), SARS-CoV-2 is the third
coronavirus to cause severe respiratory illness in humans.
Although several drugs are under investigation to treat the
disease and some have entered clinical trials, future outbreaks by
related coronaviruses originating from spill-over reservoirs are
highly likely. Thus, there is an urgent need to rapidly develop and
deploy safe and effective vaccines to immunize an extraordinarily
large number of individuals in order to protect the entire global
community from the continued threat of morbidity and mortality.
Currently, the global COVID-19 vaccine R&D landscape includes
more than 200 vaccine candidates, of which several have moved
into clinical development.3 It has been structurally and function-
ally established that the S protein, specifically the receptor-
binding domain (RBD), binds to the angiotensin-converting
enzyme 2 (ACE2) receptor on the surface of human cells to
promote host cell entry, making the viral spike an attractive
therapeutic and vaccine target.4 At least 60 vaccine platforms that
are in clinical trials involve injection of one of the recombinant
SARS-CoV-2 proteins to immunize a healthy individual to trigger a
protective immune response against future exposures; with a
large majority utilizing the spike protein. In an alternate strategy,
Yang et al. developed a rationally designed recombinant protein
vaccine comprising residues 319–545 of the SARS-CoV-2 spike-
protein RBD (Fig. 1).1 The recombinant protein was produced from
insect cells using the Bac-to-Bac Baculovirus Expression System.
Notably, proteins derived from the baculovirus expression system
generally assume a correctly folded conformation and enable
mass production in a relatively simple, rapid, and scalable manner
making them commercially feasible. Structural insights into the
purified RBD protein revealed several glycosylation sites, which
were identified and mapped to ensure they may not interfere with
ACE2 receptor recognition/binding.
Thereafter, the humoral response of the recombinant RBD, in
combination with alum as an adjuvant, was assessed upon
intramuscular injections in mice, rabbits, and non-human primates
(NHPs). Anti-RBD-specific IgG and IgM were readily detectable in
the sera of immunized mice as early as 7 days post-injection. This
antibody response was dose dependent and also displayed potent
neutralization activity both in rabbits and NHPs. Furthermore, the
authors investigated the protective effects of immunization upon
subsequent exposure to SARS-CoV-2. Vaccination with a single low
dose of RBD in mice could effectively block RBD binding to ACE2
receptors in cells in vitro in the presence of sera from immunized
mice. Similar results were seen in NHPs where sera from
immunized Macaca mulatta 7 days post-immunization could
significantly reduce SARS-CoV-2 pseudovirus infection in ACE2
expressing Huh7 cells. More importantly, two sequential intra-
muscular injections at day 0 and day 7, with either 20 μg or 40 μg
of purified RBD seemed to credibly protect NHPs from subsequent
infection by live SARS-CoV-2 when challenged intranasally 28 days
after the first dose. Lung tissue, throat swabs, and anal swabs of
the NHPs were assessed for viral genomic RNA and subgenomic
RNA (sgRNA; indicative of viral replication) 3–7 days after virus
exposure. Even though viral genomic RNA was detected in the
throat and anal swabs (but not lung tissue), no sgRNA was
detected in any tissue from the vaccinated groups indicating no
evidence of viral replication and hence, efficacious protection.
Having established the efficacy of the vaccination strategy, it is
critical to understand the mechanisms for pathogenesis and
immune pathways that contribute to the humoral and cellular
immune response induced by the vaccine. Such insights might
prove essential for the development and improvement of
effectual prophylactic and interventional strategies. The authors
observed that vaccination of the mice deficient in Cd4−/−,
Sting1−/−, Casp1−/−, Nlrp3−/− IL-1β−/−, Tlr2−/−, and Tlr4−/− (but
not Cd8−/−) led to a reduction in the induction of RBD-specific
IgG. However, RBD-vaccinated mice were also found to stimulate
the production of memory T cells—CD4+ CD44highIL-4+ , CD4+
Received: 10 August 2020 Revised: 17 August 2020 Accepted: 18 August 2020
1Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Microbiology and Physiological Systems, University of
Massachusetts Medical School, Worcester, MA, USA and 3Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA, USA
Correspondence: Guangping Gao (guangping.gao@umassmed.edu)
www.nature.com/sigtransSignal Transduction and Targeted Therapy
© The Author(s) 2020
1
2
3
4
5
6
7
8
9
0
()
;,:
CD44highIFN-γ-, and CD8+ CD44highIFN-γ—that are known to play
a vital role in mounting an antiviral response with subsequent
exposures to the pathogen. To further elucidate the role of cellular
response for this vaccination platform, adoptive transfer of
immunized sera or splenic T cells from the vaccinated mice to
naïve mice was performed. While splenic T cells did not protect
against SARS-CoV-2, the transferred sera demonstrated a strong
protective effect with no detectable viral replication in the
recipient mice after live SARS-CoV-2 challenge.
Given the unusual choice of recombinant protein used in this
study, the authors compared the neutralization potential of anti-
RBD antibodies to the other domains of the spike protein—the
extracellular domain protein (ECD), S1-subunit protein (S1) and S2-
subunit protein (S2). They found that the rationally designed
recombinant RBD vaccine had a much higher viral neutralization
activity than other forms of the spike-protein tested. The safety
profile of the vaccine was evaluated in NHPs (n= 50) and no
adverse events and abnormality in clinical pathology, hematology,
and histopathology were reported.
Taken together, this study highlights the importance of the RBD
domain in S protein immunogenicity and the rationale for
selecting it as a vaccine candidate. When the authors compared
the sera from COVID-19 patients and healthy donors for their
immunoglobulin profile, IgG and IgM levels against RBD were
elevated in COVID-19 patients. Also, this strategy based on RBD
has been reinforced by the recent findings that the majority of the
human monoclonal antibodies and the neutralizing activity is
directed against RBD in the sera of COVID-19 patients.5
Additionally, as many as six independent vaccine development
initiatives are using RBD as the recombinant protein for
immunization—one of which is already in clinical trials.3 All the
findings from this well designed and well-executed study are very
encouraging and strongly supportive of further clinical develop-
ment of this vaccine candidate.
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Fig. 1 Design and production of an RBD-based vaccine and inspecting its protective effects in in vivo models. a The Spike protein of SARS-
CoV-2 is known to be critical for virus’ entry into the cells. Rational design of the vaccine involves the insertion of a GP67 signal peptide
upstream to the RBD domain of the spike protein. The recombinant protein is produced using insect cells and the Bac-to-Bac baculovirus
expression system. The purified protein formulation is then injected via intramuscular injections in mice, rabbits, and non-human primates
(NHPs; Macaca mulatta). The sera from the injected animals are immunophenotyped to profile the immune response against the RBD protein.
IgG, IgM, and memory lymphocytes are consistently produced across all immunized animals. The indicated domains and elements of the
spike protein, including signal sequence (SS), N-terminal domain (NTD), receptor-binding domain (RBD), heptad repeat1 and 2 (HR1 and HR2),
transmembrane domain (TM), and cytoplasmic domain (CT), are marked. b NHPs are sequentially immunized on day 0 and day 7
intramuscularly with purified RBD or control treatment followed by intranasal challenge with live SARS-CoV-2 on day 28. Neutralization activity
was measured from their sera, viral load was measured from throat, lung, and anal swabs, and histopathological changes in lung tissue were
analyzed by light microscopy. Immunized NHPs displayed potent neutralization, minimal viral load with the appearance of normal lung tissue
histopathology
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